The Distribution of Human Bone Marrow Mesenchymal Stem Cells After Intravenous Transplantation into Infarcted Rats

MA Jun,GE Junbo,ZHANG Shaoheng
DOI: https://doi.org/10.3969/j.issn.1008-6358.2005.06.013
2005-01-01
Abstract:Objective: To evaluate the feasibility and safety of intravenous delivery of human bone marrow mesenchymal stem cells (MSCs) for treating myocardial infarction by tracing the distribution of transplanted cells. Methods: Primary MSCs collected from healthy volunteers were cultured and expanded in vitro. Acute myocardial infarction (AMI) was created in male SD rats by ligating left anteriordescending coronary artery. A total of 1×106 MSCs were delivered through tail vein 72 hours after MI, meanwhile the same number of cells were intravenously injected into normal and sham-operation rats, respectively. At day 3 and 30 post- transplantation, immunohistochemical staining was performed to assess the distribution of BrdU-labelled donor cells in organs such as hearts,lungs,livers,spleens, Statistical analyses were performed with one-way ANOVA by SPSS software. Results; At both 3d and 30d post-transplantation, in comparison with the in-farcted hearts, the BrdU-positive cells were found extremely less in the hearts of the normal and the sham-operation rats (P< 0. 01). At 3d post-transplantation, the transplanted MSCs in the MI rats were found more abundant in the infarcted area than in the boundary ische-mic area, the area remote from infarcted myocardium, lungs, livers and spleens(P< 0. 01). 30d later, the transplanted MSCs in the infarct area were significantly reduced, whereas the transplanted MSCs in the peri-infarct area showed no significant change and were slightly more than in the former. Conclusion: Intravenous delivery of human bone marrow mesenchymal cells may be a feasible and safe alternative for the treatment of AMI.
What problem does this paper attempt to address?